Next 10 |
home / stock / silo / silo articles
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Wednesday. The Dow traded up 0.33% to 38,840.06 ...
Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday's session following first-quarter results. Lands’ End reporte...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite surging over 1% on Wednesday. The Dow traded up 0.04% to 38,728.39 whil...
SARASOTA, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutica...
The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern aro...
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern arou...
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024. See prev...
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, Ma...
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
News, Short Squeeze, Breakout and More Instantly...
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has awarded a contract to its contract research organizati...
Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmen...
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, ...